Clinical trial · Observational
Acquired Resistant Mechanism of the First-generation EGFR TKIs
Identification of Genomic Mutation Profile Using Next Generation Sequencing for Non-small-cell Lung Cancer Patients With Activating EGFR Mutations Harboring Acquired Resistance to the First-generation EGFR TKIs.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable genetic mutations can be helpful for guiding the subsequent treatment. This study aimed to analyze the genetic profile of NSCLC harboring acquired resistance to the first-generation EGFR TKIs using next generation sequencing (NGS).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aquired Resistance | — | UNRESOLVED | — |
| EGFR TKIs | — | UNRESOLVED | — |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic: mutation profile | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- mutation profile
- timeFrame
- 10 days
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histologically proven stage IIIB or IV non-small cell lung cancer * patients harboring sensitive EGFR mutations and received first-generation EGFR-TKIs who developed acquired drug resistance * patients who can provide pre-treatment (EGFR TKIs) tumor tissues * patients with tumor lesions to be re-biopsy after drug resistance * patients must sign an informed consent indicating that they are aware of the .investigational nature of the study in keeping with the policy of the hospital. Exclusion Criteria: * History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * patients with other systemic diseases
References
Publications (0)
Data not yet available